Kevin Johnson
Founder at Medicxi Ventures (Jersey) Ltd.
Profile
Kevin Stuart Johnson is the founder of Medicxi Ventures (Jersey) Ltd.
(2015) and Inhibitaxin Ltd.
(2013).
He is currently the Executive Chairman of Levicept Ltd., Director of Morphogen-IX Ltd.
(2015-), Director of Impact Biomedicines, Inc., and Director of Rebalance (Cambridge) Ltd.
(2016-).
His former positions include Chief Executive Officer of PanGenetics BV, Chairman of Diartis Pharmaceuticals, Inc., Director of Aegerion Pharmaceuticals, Inc., Director of Acutus Medical, Inc., Director of Molecular Partners AG, Director of Stealthyx Therapeutics Ltd., Director of Versartis, Inc., Director of Capella Bioscience Ltd., Director of ApcinteX Ltd., Director of SuperX Ltd., Director of UltraHuman Ltd., Principal at MedImmune Ltd., Principal at the University of Melbourne, and Principal at the University of Cambridge.
He holds a doctorate from the University of Cambridge and an undergraduate degree from the University of Edinburgh.
Kevin Johnson active positions
Companies | Position | Start |
---|---|---|
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Chairman | - |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Founder | 2015-11-02 |
Inhibitaxin Ltd.
Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Founder | 2012-12-31 |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Director/Board Member | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Director/Board Member | 2015-10-29 |
Rebalance (Cambridge) Ltd.
Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Director/Board Member | 2016-12-05 |
Former positions of Kevin Johnson
Companies | Position | End |
---|---|---|
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Director/Board Member | 2022-02-08 |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Director/Board Member | 2021-01-28 |
Index Ventures (UK) LLP | Private Equity Investor | 2016-01-30 |
░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Kevin Johnson
University of Cambridge | Doctorate Degree |
The University of Edinburgh | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ACUTUS MEDICAL, INC. | Health Technology |
MOLECULAR PARTNERS AG | Health Technology |
Private companies | 17 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
PanGenetics BV
PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
Stealthyx Therapeutics Ltd.
Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Index Ventures (UK) LLP | Finance |
Diartis Pharmaceuticals, Inc.
Diartis Pharmaceuticals, Inc. BiotechnologyHealth Technology Diartis Pharmaceuticals, Inc. developed therapeutic proteins for the treatment of metabolic disorders. The company was founded by Jeffrey L. Clearland in December 2010 and headquartered in Redwood City, CA. | Health Technology |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Health Technology |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Commercial Services |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
Capella Bioscience Ltd.
Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Inhibitaxin Ltd.
Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Health Technology |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
SuperX Ltd.
SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Health Technology |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Commercial Services |
Rebalance (Cambridge) Ltd.
Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Kevin Johnson